Community oncologists play an important role in expanding access to clinical trials. Patel discusses the value of offering ...

Dr. Jason Mouabbi revisits the patient's Grade 2 hyperglycemia at week 6, when fasting glucose reaches 212 mg/dL.

However, the shift to precision oncology involves therapy based more on molecular profiles and the context of an individual ...

Adding stereotactic body radiation therapy (SBRT) or surgery directed at every known metastasis to first-line systemic ...

Dr. Jason Mouabbi returns to the patient case, noting improvement in the patient's osseous lesions and resolution of back ...

Dr. Jason Mouabbi presents a 59-year-old postmenopausal woman with PIK3CA-mutated HR-positive/HER2-negative advanced breast ...

Dr. Jason Mouabbi discusses additional adverse events that require attention when managing patients with PIK3CA-mutated ...

Targeted Therapies in Oncology provides evidence-based news and updates on the most current advances in therapeutics, biomarkers, pathways, biomarkers, molecular profiling, and diagnostic testing with ...

VIR-5500 and [²¹²Pb]PSV359 received FDA fast track designations for prostate cancer and solitary fibrous tumors, respectively ...

Firmonertinib is a highly brain-penetrant, mutation-selective EGFR inhibitor with activity against classical and uncommon ...

Rusfertide was approved by the FDA 1 for adults with polycythemia who require phlebotomy, based on results from the phase 3 ...

The FDA approved tucatinib with trastuzumab and pertuzumab as maintenance therapy in HER2-positive breast cancer, based on ...